CYTOKINETICS INC 4

Director Wendell Wierenga received an equity-in-lieu-of-cash award of 75 shares of Cytokinetics (CYTK) common stock valued at about $6.2K.

On July 15, 2026, Dr. Wendell Wierenga received a fully vested grant of 75 shares of Cytokinetics, Inc. common stock under the company's Equity in Lieu of Cash Retainer Program, effectively taking equity instead of cash compensation. The shares were valued at approximately $82.62 per share, implying an aggregate grant value of about $6,196, and increased his direct beneficial ownership to 35,563 shares following the award. The transaction is routine director compensation rather than an open‑market purchase or discretionary sale.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000082

Alert Tier

4